Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) — DISCOMS  

Multiple Sclerosis Clinical Trial

Official title: Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)

Status Completed

Clinical Trial Summary

Natural history research in Multiple Sclerosis (MS) suggests that risk of relapses and new Magnetic Resonance Imaging (MRI) changes diminish significantly as people age, especially in MS patients 55 or older. Thus, the need to continue MS medicines that reduce relapses and new MRI lesions may also decrease as people age, especially in those who have not had relapses or MRI scan changes for prolonged times. This study plans to learn more about the safety of stopping MS medication in this population, as compared to continuing on the medication.

Clinical Trial Description

Participants will be randomized (1:1) to one of two groups. One group will stay on their current MS medication (Continue group), and one group will discontinue their medication (Discontinue group). They will also have some extra assessments done at their regular routine MS clinic appointment and every 6 months for the next 18-24 months. The following items will be done in addition to any assessments or procedures they are already having done as part of their clinical care: - Questionnaires about the participant's quality of life including questions about health, mood, thinking, and social life - Questionnaires about the participant's MS symptoms - Test of the participant's attention, concentration, and thinking - Test of the participant's physical symptoms - In addition to any MRIs the participants may get as part of their routine care, they will also have an MRI 6 months from their enrollment into the study. ;

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

• NCT number: NCT03073603
• Study type: Interventional
• Source: University of Colorado, Denver
• Status: Completed
• Phase: Phase 4
• Start date: April 20, 2017
• Completion date: August 31, 2021